#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Eutrophication of natural water sources is closely linked to the distinctive appearance of massive and episodic proliferations of cyanobacteria .
3-1	17-31	Eutrophication	abstract[3]	new[3]	_	_
3-2	32-34	of	abstract[3]	new[3]	_	_
3-3	35-42	natural	abstract[3]|substance[5]	new[3]|new[5]	_	_
3-4	43-48	water	abstract[3]|substance|substance[5]	new[3]|new|new[5]	coref	6-30[30_0]
3-5	49-56	sources	abstract[3]|substance[5]	new[3]|new[5]	_	_
3-6	57-59	is	_	_	_	_
3-7	60-67	closely	_	_	_	_
3-8	68-74	linked	_	_	_	_
3-9	75-77	to	_	_	_	_
3-10	78-81	the	abstract[6]	new[6]	_	_
3-11	82-93	distinctive	abstract[6]	new[6]	_	_
3-12	94-104	appearance	abstract[6]	new[6]	_	_
3-13	105-107	of	abstract[6]	new[6]	_	_
3-14	108-115	massive	abstract[6]|object[7]	new[6]|new[7]	_	_
3-15	116-119	and	abstract[6]|object[7]	new[6]|new[7]	_	_
3-16	120-128	episodic	abstract[6]|object[7]	new[6]|new[7]	_	_
3-17	129-143	proliferations	abstract[6]|object[7]	new[6]|new[7]	_	_
3-18	144-146	of	abstract[6]|object[7]	new[6]|new[7]	_	_
3-19	147-160	cyanobacteria	abstract[6]|object[7]|animal	new[6]|new[7]|new	coref	4-21
3-20	161-162	.	_	_	_	_

#Text=These prokaryotic organisms do not systematically carry the expressed genes for toxin production , yet about 40 of the 150 cyanobacteria genera do possess these genes .
4-1	163-168	These	animal[9]	new[9]	_	_
4-2	169-180	prokaryotic	animal[9]	new[9]	_	_
4-3	181-190	organisms	animal[9]	new[9]	_	_
4-4	191-193	do	_	_	_	_
4-5	194-197	not	_	_	_	_
4-6	198-212	systematically	_	_	_	_
4-7	213-218	carry	_	_	_	_
4-8	219-222	the	abstract[10]	new[10]	coref	4-25[16_10]
4-9	223-232	expressed	abstract[10]	new[10]	_	_
4-10	233-238	genes	abstract[10]	new[10]	_	_
4-11	239-242	for	abstract[10]	new[10]	_	_
4-12	243-248	toxin	abstract[10]|substance|abstract[12]	new[10]|new|new[12]	coref|coref	10-23[67_12]|10-23[67_12]
4-13	249-259	production	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-14	260-261	,	_	_	_	_
4-15	262-265	yet	time[13]	new[13]	_	_
4-16	266-271	about	time[13]	new[13]	_	_
4-17	272-274	40	time[13]	new[13]	_	_
4-18	275-277	of	time[13]	new[13]	_	_
4-19	278-281	the	time[13]|animal[15]	new[13]|new[15]	_	_
4-20	282-285	150	time[13]|animal[15]	new[13]|new[15]	_	_
4-21	286-299	cyanobacteria	time[13]|animal|animal[15]	new[13]|giv|new[15]	coref	8-16[49_0]
4-22	300-306	genera	time[13]|animal[15]	new[13]|new[15]	_	_
4-23	307-309	do	_	_	_	_
4-24	310-317	possess	_	_	_	_
4-25	318-323	these	abstract[16]	giv[16]	_	_
4-26	324-329	genes	abstract[16]	giv[16]	_	_
4-27	330-331	.	_	_	_	_

#Text=For more than two decades , microcystins ( MCs ) have been the main family of cyanopeptides extensively studied .
5-1	332-335	For	_	_	_	_
5-2	336-340	more	substance[18]	new[18]	_	_
5-3	341-345	than	substance[18]	new[18]	_	_
5-4	346-349	two	time[17]|substance[18]	new[17]|new[18]	_	_
5-5	350-357	decades	time[17]|substance[18]	new[17]|new[18]	_	_
5-6	358-359	,	substance[18]	new[18]	_	_
5-7	360-372	microcystins	substance[18]	new[18]	_	_
5-8	373-374	(	_	_	_	_
5-9	375-378	MCs	object	new	coref	6-33
5-10	379-380	)	_	_	_	_
5-11	381-385	have	_	_	_	_
5-12	386-390	been	_	_	_	_
5-13	391-394	the	abstract[20]	new[20]	_	_
5-14	395-399	main	abstract[20]	new[20]	_	_
5-15	400-406	family	abstract[20]	new[20]	_	_
5-16	407-409	of	abstract[20]	new[20]	_	_
5-17	410-423	cyanopeptides	abstract[20]|abstract	new[20]|new	coref	8-6
5-18	424-435	extensively	_	_	_	_
5-19	436-443	studied	_	_	_	_
5-20	444-445	.	_	_	_	_

#Text=This dominance has been triggered by tragic incidents , such as in a Brazilian hospital in 1996 , where 52 patients undergoing dialysis succumbed to liver failure caused by contaminated water with MCs .
6-1	446-450	This	abstract[22]	new[22]	_	_
6-2	451-460	dominance	abstract[22]	new[22]	_	_
6-3	461-464	has	_	_	_	_
6-4	465-469	been	_	_	_	_
6-5	470-479	triggered	_	_	_	_
6-6	480-482	by	_	_	_	_
6-7	483-489	tragic	event[23]	new[23]	_	_
6-8	490-499	incidents	event[23]	new[23]	_	_
6-9	500-501	,	event[23]	new[23]	_	_
6-10	502-506	such	event[23]	new[23]	_	_
6-11	507-509	as	event[23]	new[23]	_	_
6-12	510-512	in	event[23]	new[23]	_	_
6-13	513-514	a	event[23]|place[24]	new[23]|new[24]	_	_
6-14	515-524	Brazilian	event[23]|place[24]	new[23]|new[24]	_	_
6-15	525-533	hospital	event[23]|place[24]	new[23]|new[24]	_	_
6-16	534-536	in	event[23]|place[24]	new[23]|new[24]	_	_
6-17	537-541	1996	event[23]|place[24]|time	new[23]|new[24]|new	_	_
6-18	542-543	,	_	_	_	_
6-19	544-549	where	_	_	_	_
6-20	550-552	52	person[26]	new[26]	_	_
6-21	553-561	patients	person[26]	new[26]	_	_
6-22	562-572	undergoing	_	_	_	_
6-23	573-581	dialysis	event	new	ana	7-2
6-24	582-591	succumbed	_	_	_	_
6-25	592-594	to	_	_	_	_
6-26	595-600	liver	object|abstract[29]	new|new[29]	coref|coref	12-8[75_0]|12-8[75_0]
6-27	601-608	failure	abstract[29]	new[29]	_	_
6-28	609-615	caused	_	_	_	_
6-29	616-618	by	_	_	_	_
6-30	619-631	contaminated	substance[30]	giv[30]	coref	7-19[0_30]
6-31	632-637	water	substance[30]	giv[30]	_	_
6-32	638-642	with	substance[30]	giv[30]	_	_
6-33	643-646	MCs	substance[30]|substance	giv[30]|giv	coref	8-13
6-34	647-648	.	_	_	_	_

#Text=Following this , the World Health Organization ( WHO ) has suggested regulation levels for MC-LR in drinking water ( 1 µg L−1 ) which was extended by the US EPA to MC-LR equivalents to include more congeners and other cyanotoxins .
7-1	649-658	Following	_	_	_	_
7-2	659-663	this	event	giv	_	_
7-3	664-665	,	_	_	_	_
7-4	666-669	the	organization[33]	new[33]	_	_
7-5	670-675	World	organization[33]	new[33]	_	_
7-6	676-682	Health	organization[33]	new[33]	_	_
7-7	683-695	Organization	organization[33]	new[33]	_	_
7-8	696-697	(	_	_	_	_
7-9	698-701	WHO	_	_	_	_
7-10	702-703	)	_	_	_	_
7-11	704-707	has	_	_	_	_
7-12	708-717	suggested	_	_	_	_
7-13	718-728	regulation	abstract|abstract[35]	new|new[35]	_	_
7-14	729-735	levels	abstract[35]	new[35]	_	_
7-15	736-739	for	abstract[35]	new[35]	_	_
7-16	740-745	MC-LR	abstract[35]|substance	new[35]|new	coref	7-33
7-17	746-748	in	_	_	_	_
7-18	749-757	drinking	_	_	_	_
7-19	758-763	water	substance	giv	_	_
7-20	764-765	(	_	_	_	_
7-21	766-767	1	quantity[39]	new[39]	_	_
7-22	768-770	µg	abstract|quantity[39]	new|new[39]	_	_
7-23	771-774	L−1	quantity[39]	new[39]	_	_
7-24	775-776	)	_	_	_	_
7-25	777-782	which	_	_	_	_
7-26	783-786	was	_	_	_	_
7-27	787-795	extended	_	_	_	_
7-28	796-798	by	_	_	_	_
7-29	799-802	the	organization[41]	new[41]	_	_
7-30	803-805	US	place|organization[41]	new|new[41]	_	_
7-31	806-809	EPA	organization[41]	new[41]	_	_
7-32	810-812	to	_	_	_	_
7-33	813-818	MC-LR	substance|object[43]	giv|new[43]	_	_
7-34	819-830	equivalents	object[43]	new[43]	_	_
7-35	831-833	to	_	_	_	_
7-36	834-841	include	_	_	_	_
7-37	842-846	more	substance[44]	new[44]	coref	10-7[61_44]
7-38	847-856	congeners	substance[44]	new[44]	_	_
7-39	857-860	and	_	_	_	_
7-40	861-866	other	object[45]	new[45]	coref	16-15[99_45]
7-41	867-878	cyanotoxins	object[45]	new[45]	_	_
7-42	879-880	.	_	_	_	_

#Text=However , several families of cyanopeptides have long been identified along with MCs isolated from common cyanobacteria , i. e. , Microcystis sp .
8-1	881-888	However	_	_	_	_
8-2	889-890	,	_	_	_	_
8-3	891-898	several	abstract[46]	new[46]	ana	9-2[0_46]
8-4	899-907	families	abstract[46]	new[46]	_	_
8-5	908-910	of	abstract[46]	new[46]	_	_
8-6	911-924	cyanopeptides	abstract[46]|object	new[46]|giv	coref	11-2
8-7	925-929	have	_	_	_	_
8-8	930-934	long	_	_	_	_
8-9	935-939	been	_	_	_	_
8-10	940-950	identified	_	_	_	_
8-11	951-956	along	_	_	_	_
8-12	957-961	with	_	_	_	_
8-13	962-965	MCs	object	giv	coref	12-1
8-14	966-974	isolated	_	_	_	_
8-15	975-979	from	_	_	_	_
8-16	980-986	common	animal[49]	giv[49]	coref	16-7[0_49]
8-17	987-1000	cyanobacteria	animal[49]	giv[49]	_	_
8-18	1001-1002	,	_	_	_	_
8-19	1003-1005	i.	_	_	_	_
8-20	1006-1008	e.	_	_	_	_
8-21	1009-1010	,	_	_	_	_
8-22	1011-1022	Microcystis	abstract|animal[51]	new|new[51]	_	_
8-23	1023-1025	sp	animal[51]	new[51]	_	_
8-24	1026-1027	.	_	_	_	_

#Text=Amongst them , cyanopeptolins , anabaenopeptins ( APs ) , aerucyclamides , aeruginosines , and microginins are to mention when specifying the dominant families .
9-1	1028-1035	Amongst	_	_	_	_
9-2	1036-1040	them	abstract	giv	coref	9-22[59_0]
9-3	1041-1042	,	_	_	_	_
9-4	1043-1057	cyanopeptolins	person	new	_	_
9-5	1058-1059	,	_	_	_	_
9-6	1060-1075	anabaenopeptins	abstract	new	appos	9-8
9-7	1076-1077	(	_	_	_	_
9-8	1078-1081	APs	abstract	giv	coref	15-9
9-9	1082-1083	)	_	_	_	_
9-10	1084-1085	,	_	_	_	_
9-11	1086-1100	aerucyclamides	abstract	new	_	_
9-12	1101-1102	,	_	_	_	_
9-13	1103-1116	aeruginosines	abstract	new	_	_
9-14	1117-1118	,	_	_	_	_
9-15	1119-1122	and	_	_	_	_
9-16	1123-1134	microginins	substance	new	_	_
9-17	1135-1138	are	_	_	_	_
9-18	1139-1141	to	_	_	_	_
9-19	1142-1149	mention	_	_	_	_
9-20	1150-1154	when	_	_	_	_
9-21	1155-1165	specifying	_	_	_	_
9-22	1166-1169	the	abstract[59]	giv[59]	coref	26-10[151_59]
9-23	1170-1178	dominant	abstract[59]	giv[59]	_	_
9-24	1179-1187	families	abstract[59]	giv[59]	_	_
9-25	1188-1189	.	_	_	_	_

#Text=Still , the high diversity of produced congeners from each family and the little information known about factors and mechanisms linked to their production greatly complicates their study .
10-1	1190-1195	Still	_	_	_	_
10-2	1196-1197	,	_	_	_	_
10-3	1198-1201	the	abstract[60]	new[60]	_	_
10-4	1202-1206	high	abstract[60]	new[60]	_	_
10-5	1207-1216	diversity	abstract[60]	new[60]	_	_
10-6	1217-1219	of	abstract[60]	new[60]	_	_
10-7	1220-1228	produced	abstract[60]|substance[61]	new[60]|giv[61]	coref	15-8[88_61]
10-8	1229-1238	congeners	abstract[60]|substance[61]	new[60]|giv[61]	_	_
10-9	1239-1243	from	abstract[60]|substance[61]	new[60]|giv[61]	_	_
10-10	1244-1248	each	abstract[60]|substance[61]|person[62]	new[60]|giv[61]|new[62]	coref	18-13[108_62]
10-11	1249-1255	family	abstract[60]|substance[61]|person[62]	new[60]|giv[61]|new[62]	_	_
10-12	1256-1259	and	_	_	_	_
10-13	1260-1263	the	abstract[63]	new[63]	_	_
10-14	1264-1270	little	abstract[63]	new[63]	_	_
10-15	1271-1282	information	abstract[63]	new[63]	_	_
10-16	1283-1288	known	_	_	_	_
10-17	1289-1294	about	_	_	_	_
10-18	1295-1302	factors	abstract	new	_	_
10-19	1303-1306	and	_	_	_	_
10-20	1307-1317	mechanisms	abstract	new	ana	10-23
10-21	1318-1324	linked	_	_	_	_
10-22	1325-1327	to	_	_	_	_
10-23	1328-1333	their	abstract|abstract[67]	giv|giv[67]	ana|ana	10-27|10-27
10-24	1334-1344	production	abstract[67]	giv[67]	_	_
10-25	1345-1352	greatly	_	_	_	_
10-26	1353-1364	complicates	_	_	_	_
10-27	1365-1370	their	abstract|abstract[69]	giv|new[69]	_	_
10-28	1371-1376	study	abstract[69]	new[69]	_	_
10-29	1377-1378	.	_	_	_	_

#Text=Potential cyanopeptides toxicity critically depends on the variants structure , but is still misunderstood and poorly documented .
11-1	1379-1388	Potential	abstract[71]	new[71]	coref	17-20[104_71]
11-2	1389-1402	cyanopeptides	substance|abstract[71]	giv|new[71]	coref	17-14[102_0]
11-3	1403-1411	toxicity	abstract[71]	new[71]	_	_
11-4	1412-1422	critically	_	_	_	_
11-5	1423-1430	depends	_	_	_	_
11-6	1431-1433	on	_	_	_	_
11-7	1434-1437	the	abstract[73]	new[73]	coref	19-4[114_73]
11-8	1438-1446	variants	object|abstract[73]	new|new[73]	coref	27-19[162_0]
11-9	1447-1456	structure	abstract[73]	new[73]	_	_
11-10	1457-1458	,	_	_	_	_
11-11	1459-1462	but	_	_	_	_
11-12	1463-1465	is	_	_	_	_
11-13	1466-1471	still	_	_	_	_
11-14	1472-1485	misunderstood	_	_	_	_
11-15	1486-1489	and	_	_	_	_
11-16	1490-1496	poorly	_	_	_	_
11-17	1497-1507	documented	_	_	_	_
11-18	1508-1509	.	_	_	_	_

#Text=MCs are hepatotoxic and readily accumulated in the liver from the specific binding to protein phosphatases 1 and 2A .
12-1	1510-1513	MCs	object	giv	coref	19-36[123_0]
12-2	1514-1517	are	_	_	_	_
12-3	1518-1529	hepatotoxic	_	_	_	_
12-4	1530-1533	and	_	_	_	_
12-5	1534-1541	readily	_	_	_	_
12-6	1542-1553	accumulated	_	_	_	_
12-7	1554-1556	in	_	_	_	_
12-8	1557-1560	the	object[75]	giv[75]	coref	13-18[0_75]
12-9	1561-1566	liver	object[75]	giv[75]	_	_
12-10	1567-1571	from	_	_	_	_
12-11	1572-1575	the	event[76]	new[76]	_	_
12-12	1576-1584	specific	event[76]	new[76]	_	_
12-13	1585-1592	binding	event[76]	new[76]	_	_
12-14	1593-1595	to	event[76]	new[76]	_	_
12-15	1596-1603	protein	event[76]|substance|abstract[78]	new[76]|new|new[78]	coref|coref|coref|coref	15-24|15-24[93_78]|15-24|15-24[93_78]
12-16	1604-1616	phosphatases	event[76]|abstract[78]	new[76]|new[78]	_	_
12-17	1617-1618	1	event[76]|abstract[78]	new[76]|new[78]	_	_
12-18	1619-1622	and	event[76]|abstract[78]	new[76]|new[78]	_	_
12-19	1623-1625	2A	event[76]|abstract[78]	new[76]|new[78]	_	_
12-20	1626-1627	.	_	_	_	_

#Text=The latter causes disruption of cellular homeostasis , and , in most acute cases , leads to liver necrosis , as well as colorectal and liver cancer .
13-1	1628-1631	The	_	_	_	_
13-2	1632-1638	latter	_	_	_	_
13-3	1639-1645	causes	abstract	new	coref|none	19-17[118_0]|13-3[0_118]
13-4	1646-1656	disruption	abstract[79]	new[79]	_	_
13-5	1657-1659	of	abstract[79]	new[79]	_	_
13-6	1660-1668	cellular	abstract[79]|abstract[80]	new[79]|new[80]	_	_
13-7	1669-1680	homeostasis	abstract[79]|abstract[80]	new[79]|new[80]	_	_
13-8	1681-1682	,	_	_	_	_
13-9	1683-1686	and	_	_	_	_
13-10	1687-1688	,	_	_	_	_
13-11	1689-1691	in	_	_	_	_
13-12	1692-1696	most	abstract[81]	new[81]	_	_
13-13	1697-1702	acute	abstract[81]	new[81]	_	_
13-14	1703-1708	cases	abstract[81]	new[81]	_	_
13-15	1709-1710	,	_	_	_	_
13-16	1711-1716	leads	_	_	_	_
13-17	1717-1719	to	_	_	_	_
13-18	1720-1725	liver	object|object[83]	giv|new[83]	_	_
13-19	1726-1734	necrosis	object[83]	new[83]	_	_
13-20	1735-1736	,	_	_	_	_
13-21	1737-1739	as	_	_	_	_
13-22	1740-1744	well	_	_	_	_
13-23	1745-1747	as	_	_	_	_
13-24	1748-1758	colorectal	abstract[84]	new[84]	_	_
13-25	1759-1762	and	abstract[84]	new[84]	_	_
13-26	1763-1768	liver	abstract[84]	new[84]	_	_
13-27	1769-1775	cancer	abstract[84]	new[84]	_	_
13-28	1776-1777	.	_	_	_	_

#Text=Thus far , bioactive APs are considered non-toxic .
14-1	1778-1782	Thus	_	_	_	_
14-2	1783-1786	far	_	_	_	_
14-3	1787-1788	,	_	_	_	_
14-4	1789-1798	bioactive	object[85]	new[85]	_	_
14-5	1799-1802	APs	object[85]	new[85]	_	_
14-6	1803-1806	are	_	_	_	_
14-7	1807-1817	considered	_	_	_	_
14-8	1818-1827	non-toxic	_	_	_	_
14-9	1828-1829	.	_	_	_	_

#Text=Nevertheless , a few studies suggest that some APs congeners , such as AP-A , may demonstrate the potential to inhibit protease and protein phosphatases .
15-1	1830-1842	Nevertheless	_	_	_	_
15-2	1843-1844	,	_	_	_	_
15-3	1845-1846	a	abstract[86]	new[86]	_	_
15-4	1847-1850	few	abstract[86]	new[86]	_	_
15-5	1851-1858	studies	abstract[86]	new[86]	_	_
15-6	1859-1866	suggest	_	_	_	_
15-7	1867-1871	that	_	_	_	_
15-8	1872-1876	some	substance[88]	giv[88]	coref	19-24[120_88]
15-9	1877-1880	APs	abstract|substance[88]	giv|giv[88]	coref	19-39[124_0]
15-10	1881-1890	congeners	substance[88]	giv[88]	_	_
15-11	1891-1892	,	substance[88]	giv[88]	_	_
15-12	1893-1897	such	substance[88]	giv[88]	_	_
15-13	1898-1900	as	substance[88]	giv[88]	_	_
15-14	1901-1905	AP-A	substance[88]|substance	giv[88]|new	_	_
15-15	1906-1907	,	_	_	_	_
15-16	1908-1911	may	_	_	_	_
15-17	1912-1923	demonstrate	_	_	_	_
15-18	1924-1927	the	abstract[90]	new[90]	_	_
15-19	1928-1937	potential	abstract[90]	new[90]	_	_
15-20	1938-1940	to	_	_	_	_
15-21	1941-1948	inhibit	_	_	_	_
15-22	1949-1957	protease	substance	new	_	_
15-23	1958-1961	and	_	_	_	_
15-24	1962-1969	protein	substance|abstract[93]	giv|giv[93]	_	_
15-25	1970-1982	phosphatases	abstract[93]	giv[93]	_	_
15-26	1983-1984	.	_	_	_	_

#Text=Moreover , AP-B and -F induce cyanobacteria lysis , ultimately affecting the bioavailability of other cell-bound cyanotoxins .
16-1	1985-1993	Moreover	_	_	_	_
16-2	1994-1995	,	_	_	_	_
16-3	1996-2000	AP-B	substance	new	_	_
16-4	2001-2004	and	_	_	_	_
16-5	2005-2007	-F	abstract	new	_	_
16-6	2008-2014	induce	_	_	_	_
16-7	2015-2028	cyanobacteria	animal|abstract[97]	giv|new[97]	ana|ana	27-7[0_97]|27-7[0_97]
16-8	2029-2034	lysis	abstract[97]	new[97]	_	_
16-9	2035-2036	,	_	_	_	_
16-10	2037-2047	ultimately	_	_	_	_
16-11	2048-2057	affecting	_	_	_	_
16-12	2058-2061	the	abstract[98]	new[98]	_	_
16-13	2062-2077	bioavailability	abstract[98]	new[98]	_	_
16-14	2078-2080	of	abstract[98]	new[98]	_	_
16-15	2081-2086	other	abstract[98]|object[99]	new[98]|giv[99]	coref	31-6[199_99]
16-16	2087-2097	cell-bound	abstract[98]|object[99]	new[98]|giv[99]	_	_
16-17	2098-2109	cyanotoxins	abstract[98]|object[99]	new[98]|giv[99]	_	_
16-18	2110-2111	.	_	_	_	_

#Text=Accordingly , much still needs to be done on the unambiguous identification of these cyanopeptides and the assessment of their potential toxicity .
17-1	2112-2123	Accordingly	_	_	_	_
17-2	2124-2125	,	_	_	_	_
17-3	2126-2130	much	_	_	_	_
17-4	2131-2136	still	_	_	_	_
17-5	2137-2142	needs	_	_	_	_
17-6	2143-2145	to	_	_	_	_
17-7	2146-2148	be	_	_	_	_
17-8	2149-2153	done	_	_	_	_
17-9	2154-2156	on	_	_	_	_
17-10	2157-2160	the	abstract[100]|abstract[101]	new[100]|new[101]	_	_
17-11	2161-2172	unambiguous	abstract[100]|abstract[101]	new[100]|new[101]	_	_
17-12	2173-2187	identification	abstract[100]|abstract[101]	new[100]|new[101]	_	_
17-13	2188-2190	of	abstract[100]|abstract[101]	new[100]|new[101]	_	_
17-14	2191-2196	these	abstract[100]|abstract[101]|abstract[102]	new[100]|new[101]|giv[102]	coref	19-28[122_102]
17-15	2197-2210	cyanopeptides	abstract[100]|abstract[101]|abstract[102]	new[100]|new[101]|giv[102]	_	_
17-16	2211-2214	and	abstract[101]	new[101]	_	_
17-17	2215-2218	the	abstract[101]|abstract[103]	new[101]|new[103]	_	_
17-18	2219-2229	assessment	abstract[101]|abstract[103]	new[101]|new[103]	_	_
17-19	2230-2232	of	abstract[101]|abstract[103]	new[101]|new[103]	_	_
17-20	2233-2238	their	abstract[101]|abstract[103]|abstract[104]	new[101]|new[103]|giv[104]	_	_
17-21	2239-2248	potential	abstract[101]|abstract[103]|abstract[104]	new[101]|new[103]|giv[104]	_	_
17-22	2249-2257	toxicity	abstract[101]|abstract[103]|abstract[104]	new[101]|new[103]|giv[104]	_	_
17-23	2258-2259	.	_	_	_	_

#Text=Cyanopeptide ’s structures are characterized by cyclic or linear non-ribosomal peptides , each family possessing a characteristic substructure and some variable amino acids and peptides .
18-1	2260-2272	Cyanopeptide	abstract[105]|abstract[106]	new[105]|new[106]	_	_
18-2	2273-2275	’s	abstract[105]|abstract[106]	new[105]|new[106]	_	_
18-3	2276-2286	structures	abstract[106]	new[106]	_	_
18-4	2287-2290	are	_	_	_	_
18-5	2291-2304	characterized	_	_	_	_
18-6	2305-2307	by	_	_	_	_
18-7	2308-2314	cyclic	substance[107]	new[107]	coref	18-25[0_107]
18-8	2315-2317	or	substance[107]	new[107]	_	_
18-9	2318-2324	linear	substance[107]	new[107]	_	_
18-10	2325-2338	non-ribosomal	substance[107]	new[107]	_	_
18-11	2339-2347	peptides	substance[107]	new[107]	_	_
18-12	2348-2349	,	_	_	_	_
18-13	2350-2354	each	person[108]	giv[108]	_	_
18-14	2355-2361	family	person[108]	giv[108]	_	_
18-15	2362-2372	possessing	_	_	_	_
18-16	2373-2374	a	abstract[109]	new[109]	_	_
18-17	2375-2389	characteristic	abstract[109]	new[109]	_	_
18-18	2390-2402	substructure	abstract[109]	new[109]	_	_
18-19	2403-2406	and	_	_	_	_
18-20	2407-2411	some	abstract[111]	new[111]	coref	26-18[153_111]
18-21	2412-2420	variable	abstract[111]	new[111]	_	_
18-22	2421-2426	amino	object|abstract[111]	new|new[111]	_	_
18-23	2427-2432	acids	abstract[111]	new[111]	_	_
18-24	2433-2436	and	_	_	_	_
18-25	2437-2445	peptides	substance	giv	_	_
18-26	2446-2447	.	_	_	_	_

#Text=These variations in the core structure of each cyanopeptide multiply the number of combinations which is the cause of the large variety of potential congeners ; to date , more than 500 cyanopeptides , including 240 MCs and 96 APs have been identified .
19-1	2448-2453	These	abstract[113]	new[113]	_	_
19-2	2454-2464	variations	abstract[113]	new[113]	_	_
19-3	2465-2467	in	abstract[113]	new[113]	_	_
19-4	2468-2471	the	abstract[113]|abstract[114]	new[113]|giv[114]	coref	25-3[142_114]
19-5	2472-2476	core	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
19-6	2477-2486	structure	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
19-7	2487-2489	of	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
19-8	2490-2494	each	abstract[113]|abstract[114]|substance[115]	new[113]|giv[114]|new[115]	_	_
19-9	2495-2507	cyanopeptide	abstract[113]|abstract[114]|substance[115]	new[113]|giv[114]|new[115]	_	_
19-10	2508-2516	multiply	_	_	_	_
19-11	2517-2520	the	abstract[116]	new[116]	_	_
19-12	2521-2527	number	abstract[116]	new[116]	_	_
19-13	2528-2530	of	abstract[116]	new[116]	_	_
19-14	2531-2543	combinations	abstract[116]|abstract	new[116]|new	coref	26-3[150_0]
19-15	2544-2549	which	_	_	_	_
19-16	2550-2552	is	_	_	_	_
19-17	2553-2556	the	abstract[118]	new[118]	_	_
19-18	2557-2562	cause	abstract[118]	new[118]	_	_
19-19	2563-2565	of	abstract[118]	new[118]	_	_
19-20	2566-2569	the	abstract[118]|abstract[119]	new[118]|new[119]	_	_
19-21	2570-2575	large	abstract[118]|abstract[119]	new[118]|new[119]	_	_
19-22	2576-2583	variety	abstract[118]|abstract[119]	new[118]|new[119]	_	_
19-23	2584-2586	of	abstract[118]|abstract[119]	new[118]|new[119]	_	_
19-24	2587-2596	potential	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	coref	27-16[0_120]
19-25	2597-2606	congeners	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-26	2607-2608	;	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-27	2609-2611	to	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-28	2612-2616	date	abstract[118]|abstract[119]|substance[120]|time|abstract[122]	new[118]|new[119]|giv[120]|new|giv[122]	coref|coref|coref|coref	26-34[156_122]|26-37|26-34[156_122]|26-37
19-29	2617-2618	,	abstract[118]|abstract[119]|substance[120]|abstract[122]	new[118]|new[119]|giv[120]|giv[122]	_	_
19-30	2619-2623	more	abstract[118]|abstract[119]|substance[120]|abstract[122]	new[118]|new[119]|giv[120]|giv[122]	_	_
19-31	2624-2628	than	abstract[118]|abstract[119]|substance[120]|abstract[122]	new[118]|new[119]|giv[120]|giv[122]	_	_
19-32	2629-2632	500	abstract[118]|abstract[119]|substance[120]|abstract[122]	new[118]|new[119]|giv[120]|giv[122]	_	_
19-33	2633-2646	cyanopeptides	abstract[118]|abstract[119]|substance[120]|abstract[122]	new[118]|new[119]|giv[120]|giv[122]	_	_
19-34	2647-2648	,	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-35	2649-2658	including	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-36	2659-2662	240	abstract[118]|abstract[119]|substance[120]|object[123]	new[118]|new[119]|giv[120]|giv[123]	coref	20-4[0_123]
19-37	2663-2666	MCs	abstract[118]|abstract[119]|substance[120]|object[123]	new[118]|new[119]|giv[120]|giv[123]	_	_
19-38	2667-2670	and	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-39	2671-2673	96	abstract[118]|abstract[119]|substance[120]|abstract[124]	new[118]|new[119]|giv[120]|giv[124]	coref	23-1[0_124]
19-40	2674-2677	APs	abstract[118]|abstract[119]|substance[120]|abstract[124]	new[118]|new[119]|giv[120]|giv[124]	_	_
19-41	2678-2682	have	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-42	2683-2687	been	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-43	2688-2698	identified	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
19-44	2699-2700	.	_	_	_	_

#Text=More specifically , MCs are cyclic heptapeptides (
20-1	2701-2705	More	_	_	_	_
20-2	2706-2718	specifically	_	_	_	_
20-3	2719-2720	,	_	_	_	_
20-4	2721-2724	MCs	substance	giv	coref	20-6[126_0]
20-5	2725-2728	are	_	_	_	_
20-6	2729-2735	cyclic	substance[126]	giv[126]	_	_
20-7	2736-2749	heptapeptides	substance[126]	giv[126]	_	_
20-8	2750-2751	(	_	_	_	_

#Text=Figure 1
21-1	2752-2758	Figure	object[127]	new[127]	coref	24-1[140_127]
21-2	2759-2760	1	object[127]	new[127]	_	_

#Text=) with a characteristic β-amino acid moiety named Adda ( 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid ) , and two distinctive positions with the highest variation of monomers ( X and Z ) .
22-1	2761-2762	)	_	_	_	_
22-2	2763-2767	with	_	_	_	_
22-3	2768-2769	a	abstract[130]	new[130]	_	_
22-4	2770-2784	characteristic	abstract[130]	new[130]	_	_
22-5	2785-2792	β-amino	object|abstract[130]	new|new[130]	_	_
22-6	2793-2797	acid	substance|abstract[130]	new|new[130]	appos	22-11[132_0]
22-7	2798-2804	moiety	abstract[130]	new[130]	_	_
22-8	2805-2810	named	_	_	_	_
22-9	2811-2815	Adda	person	new	_	_
22-10	2816-2817	(	_	_	_	_
22-11	2818-2877	3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic	substance[132]	giv[132]	coref	25-19[0_132]
22-12	2878-2882	acid	substance[132]	giv[132]	_	_
22-13	2883-2884	)	_	_	_	_
22-14	2885-2886	,	_	_	_	_
22-15	2887-2890	and	_	_	_	_
22-16	2891-2894	two	abstract[133]	new[133]	_	_
22-17	2895-2906	distinctive	abstract[133]	new[133]	_	_
22-18	2907-2916	positions	abstract[133]	new[133]	_	_
22-19	2917-2921	with	abstract[133]	new[133]	_	_
22-20	2922-2925	the	abstract[133]|abstract[134]	new[133]|new[134]	_	_
22-21	2926-2933	highest	abstract[133]|abstract[134]	new[133]|new[134]	_	_
22-22	2934-2943	variation	abstract[133]|abstract[134]	new[133]|new[134]	_	_
22-23	2944-2946	of	abstract[133]|abstract[134]	new[133]|new[134]	_	_
22-24	2947-2955	monomers	abstract[133]|abstract[134]|abstract	new[133]|new[134]|new	_	_
22-25	2956-2957	(	_	_	_	_
22-26	2958-2959	X	person	new	_	_
22-27	2960-2963	and	_	_	_	_
22-28	2964-2965	Z	_	_	_	_
22-29	2966-2967	)	_	_	_	_
22-30	2968-2969	.	_	_	_	_

#Text=APs are cyclic peptides bound through a characteristic ureido-linkage (
23-1	2970-2973	APs	substance	giv	coref	23-3[138_0]
23-2	2974-2977	are	_	_	_	_
23-3	2978-2984	cyclic	substance[138]	giv[138]	ana	25-3[0_138]
23-4	2985-2993	peptides	substance[138]	giv[138]	_	_
23-5	2994-2999	bound	_	_	_	_
23-6	3000-3007	through	_	_	_	_
23-7	3008-3009	a	abstract[139]	new[139]	_	_
23-8	3010-3024	characteristic	abstract[139]	new[139]	_	_
23-9	3025-3039	ureido-linkage	abstract[139]	new[139]	_	_
23-10	3040-3041	(	_	_	_	_

#Text=Figure 1
24-1	3042-3048	Figure	object[140]	giv[140]	_	_
24-2	3049-3050	1	object[140]	giv[140]	_	_

#Text=) ; their structure is characterized as the following : AA1-CO-[Lys-AA3-AA4-MeAA5-AA6 ] with AA representing a variable amino acid residues and brackets , including the cyclic structure .
25-1	3051-3052	)	_	_	_	_
25-2	3053-3054	;	_	_	_	_
25-3	3055-3060	their	substance|abstract[142]	giv|giv[142]	coref|coref	25-25[148_142]|25-25[148_142]
25-4	3061-3070	structure	abstract[142]	giv[142]	_	_
25-5	3071-3073	is	_	_	_	_
25-6	3074-3087	characterized	_	_	_	_
25-7	3088-3090	as	_	_	_	_
25-8	3091-3094	the	_	_	_	_
25-9	3095-3104	following	_	_	_	_
25-10	3105-3106	:	_	_	_	_
25-11	3107-3136	AA1-CO-[Lys-AA3-AA4-MeAA5-AA6	abstract	new	_	_
25-12	3137-3138	]	_	_	_	_
25-13	3139-3143	with	_	_	_	_
25-14	3144-3146	AA	abstract	new	_	_
25-15	3147-3159	representing	_	_	_	_
25-16	3160-3161	a	abstract[146]	new[146]	_	_
25-17	3162-3170	variable	abstract[146]	new[146]	_	_
25-18	3171-3176	amino	abstract[146]	new[146]	_	_
25-19	3177-3181	acid	substance|abstract[146]	giv|new[146]	coref	26-6
25-20	3182-3190	residues	abstract[146]	new[146]	_	_
25-21	3191-3194	and	_	_	_	_
25-22	3195-3203	brackets	abstract[147]	new[147]	_	_
25-23	3204-3205	,	abstract[147]	new[147]	_	_
25-24	3206-3215	including	abstract[147]	new[147]	_	_
25-25	3216-3219	the	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
25-26	3220-3226	cyclic	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
25-27	3227-3236	structure	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
25-28	3237-3238	.	_	_	_	_

#Text=Based on the various amino acid combinations identified for these two families , an extensive list of potential amino acids per variable sites can be proposed to enumerate all possible theoretical combinations of cyanopeptides identifiable to date .
26-1	3239-3244	Based	_	_	_	_
26-2	3245-3247	on	_	_	_	_
26-3	3248-3251	the	abstract[150]	giv[150]	coref	26-29[155_150]
26-4	3252-3259	various	abstract[150]	giv[150]	_	_
26-5	3260-3265	amino	abstract[150]	giv[150]	_	_
26-6	3266-3270	acid	substance|abstract[150]	giv|giv[150]	_	_
26-7	3271-3283	combinations	abstract[150]	giv[150]	_	_
26-8	3284-3294	identified	_	_	_	_
26-9	3295-3298	for	_	_	_	_
26-10	3299-3304	these	abstract[151]	giv[151]	coref	13-3[0_151]
26-11	3305-3308	two	abstract[151]	giv[151]	_	_
26-12	3309-3317	families	abstract[151]	giv[151]	_	_
26-13	3318-3319	,	_	_	_	_
26-14	3320-3322	an	abstract[152]	new[152]	_	_
26-15	3323-3332	extensive	abstract[152]	new[152]	_	_
26-16	3333-3337	list	abstract[152]	new[152]	_	_
26-17	3338-3340	of	abstract[152]	new[152]	_	_
26-18	3341-3350	potential	abstract[152]|abstract[153]	new[152]|giv[153]	coref	27-36[164_153]
26-19	3351-3356	amino	abstract[152]|abstract[153]	new[152]|giv[153]	_	_
26-20	3357-3362	acids	abstract[152]|abstract[153]	new[152]|giv[153]	_	_
26-21	3363-3366	per	abstract[152]|abstract[153]	new[152]|giv[153]	_	_
26-22	3367-3375	variable	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|new[154]	_	_
26-23	3376-3381	sites	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|new[154]	_	_
26-24	3382-3385	can	_	_	_	_
26-25	3386-3388	be	_	_	_	_
26-26	3389-3397	proposed	_	_	_	_
26-27	3398-3400	to	_	_	_	_
26-28	3401-3410	enumerate	_	_	_	_
26-29	3411-3414	all	abstract[155]	giv[155]	coref	27-3[158_155]
26-30	3415-3423	possible	abstract[155]	giv[155]	_	_
26-31	3424-3435	theoretical	abstract[155]	giv[155]	_	_
26-32	3436-3448	combinations	abstract[155]	giv[155]	_	_
26-33	3449-3451	of	abstract[155]	giv[155]	_	_
26-34	3452-3465	cyanopeptides	abstract[155]|object[156]	giv[155]|giv[156]	coref	37-16[252_156]
26-35	3466-3478	identifiable	abstract[155]|object[156]	giv[155]|giv[156]	_	_
26-36	3479-3481	to	_	_	_	_
26-37	3482-3486	date	time	giv	_	_
26-38	3487-3488	.	_	_	_	_

#Text=Based on the proposed combinations , one could theoretically propose a significantly higher number of congeners , although most of the variants may not occur naturally in practice , due to the low frequency of some amino acids in the possible combinations .
27-1	3489-3494	Based	_	_	_	_
27-2	3495-3497	on	_	_	_	_
27-3	3498-3501	the	abstract[158]	giv[158]	coref	27-40[165_158]
27-4	3502-3510	proposed	abstract[158]	giv[158]	_	_
27-5	3511-3523	combinations	abstract[158]	giv[158]	_	_
27-6	3524-3525	,	_	_	_	_
27-7	3526-3529	one	abstract	giv	_	_
27-8	3530-3535	could	_	_	_	_
27-9	3536-3549	theoretically	_	_	_	_
27-10	3550-3557	propose	_	_	_	_
27-11	3558-3559	a	quantity[160]	new[160]	_	_
27-12	3560-3573	significantly	quantity[160]	new[160]	_	_
27-13	3574-3580	higher	quantity[160]	new[160]	_	_
27-14	3581-3587	number	quantity[160]	new[160]	_	_
27-15	3588-3590	of	quantity[160]	new[160]	_	_
27-16	3591-3600	congeners	quantity[160]|substance	new[160]|giv	coref	37-29[255_0]
27-17	3601-3602	,	_	_	_	_
27-18	3603-3611	although	_	_	_	_
27-19	3612-3616	most	object[162]	giv[162]	_	_
27-20	3617-3619	of	object[162]	giv[162]	_	_
27-21	3620-3623	the	object[162]	giv[162]	_	_
27-22	3624-3632	variants	object[162]	giv[162]	_	_
27-23	3633-3636	may	_	_	_	_
27-24	3637-3640	not	_	_	_	_
27-25	3641-3646	occur	_	_	_	_
27-26	3647-3656	naturally	_	_	_	_
27-27	3657-3659	in	_	_	_	_
27-28	3660-3668	practice	_	_	_	_
27-29	3669-3670	,	_	_	_	_
27-30	3671-3674	due	_	_	_	_
27-31	3675-3677	to	_	_	_	_
27-32	3678-3681	the	abstract[163]	new[163]	_	_
27-33	3682-3685	low	abstract[163]	new[163]	_	_
27-34	3686-3695	frequency	abstract[163]	new[163]	_	_
27-35	3696-3698	of	abstract[163]	new[163]	_	_
27-36	3699-3703	some	abstract[163]|abstract[164]	new[163]|giv[164]	_	_
27-37	3704-3709	amino	abstract[163]|abstract[164]	new[163]|giv[164]	_	_
27-38	3710-3715	acids	abstract[163]|abstract[164]	new[163]|giv[164]	_	_
27-39	3716-3718	in	abstract[163]|abstract[164]	new[163]|giv[164]	_	_
27-40	3719-3722	the	abstract[163]|abstract[164]|abstract[165]	new[163]|giv[164]|giv[165]	_	_
27-41	3723-3731	possible	abstract[163]|abstract[164]|abstract[165]	new[163]|giv[164]|giv[165]	_	_
27-42	3732-3744	combinations	abstract[163]|abstract[164]|abstract[165]	new[163]|giv[164]|giv[165]	_	_
27-43	3745-3746	.	_	_	_	_

#Text=High-resolution mass spectrometry ( HRMS ) can use exact mass measurement coupled to database and software packages to become an increasingly more effective tool regarding the accurate identification of the suspect and unknown compounds without the use of certified standards , where target analysis is unfeasible .
28-1	3747-3762	High-resolution	abstract[167]	new[167]	appos	28-5[0_167]
28-2	3763-3767	mass	quantity|abstract[167]	new|new[167]	coref	28-10
28-3	3768-3780	spectrometry	abstract[167]	new[167]	_	_
28-4	3781-3782	(	_	_	_	_
28-5	3783-3787	HRMS	abstract	giv	coref	32-20
28-6	3788-3789	)	_	_	_	_
28-7	3790-3793	can	_	_	_	_
28-8	3794-3797	use	_	_	_	_
28-9	3798-3803	exact	abstract[170]	new[170]	_	_
28-10	3804-3808	mass	quantity|abstract[170]	giv|new[170]	coref	33-9[211_0]
28-11	3809-3820	measurement	abstract[170]	new[170]	_	_
28-12	3821-3828	coupled	_	_	_	_
28-13	3829-3831	to	_	_	_	_
28-14	3832-3840	database	abstract	new	_	_
28-15	3841-3844	and	_	_	_	_
28-16	3845-3853	software	abstract|abstract[173]	new|new[173]	_	_
28-17	3854-3862	packages	abstract[173]	new[173]	_	_
28-18	3863-3865	to	_	_	_	_
28-19	3866-3872	become	_	_	_	_
28-20	3873-3875	an	_	_	_	_
28-21	3876-3888	increasingly	_	_	_	_
28-22	3889-3893	more	_	_	_	_
28-23	3894-3903	effective	_	_	_	_
28-24	3904-3908	tool	_	_	_	_
28-25	3909-3918	regarding	_	_	_	_
28-26	3919-3922	the	abstract[174]	new[174]	coref	32-12[0_174]
28-27	3923-3931	accurate	abstract[174]	new[174]	_	_
28-28	3932-3946	identification	abstract[174]	new[174]	_	_
28-29	3947-3949	of	abstract[174]	new[174]	_	_
28-30	3950-3953	the	abstract[174]|substance[175]	new[174]|new[175]	_	_
28-31	3954-3961	suspect	abstract[174]|substance[175]	new[174]|new[175]	_	_
28-32	3962-3965	and	abstract[174]|substance[175]	new[174]|new[175]	_	_
28-33	3966-3973	unknown	abstract[174]|substance[175]	new[174]|new[175]	_	_
28-34	3974-3983	compounds	abstract[174]|substance[175]	new[174]|new[175]	_	_
28-35	3984-3991	without	abstract[174]|substance[175]	new[174]|new[175]	_	_
28-36	3992-3995	the	abstract[174]|substance[175]|abstract[176]	new[174]|new[175]|new[176]	_	_
28-37	3996-3999	use	abstract[174]|substance[175]|abstract[176]	new[174]|new[175]|new[176]	_	_
28-38	4000-4002	of	abstract[174]|substance[175]|abstract[176]	new[174]|new[175]|new[176]	_	_
28-39	4003-4012	certified	abstract[174]|substance[175]|abstract[176]|abstract[177]	new[174]|new[175]|new[176]|new[177]	_	_
28-40	4013-4022	standards	abstract[174]|substance[175]|abstract[176]|abstract[177]	new[174]|new[175]|new[176]|new[177]	_	_
28-41	4023-4024	,	_	_	_	_
28-42	4025-4030	where	_	_	_	_
28-43	4031-4037	target	abstract|abstract[179]	new|new[179]	coref|coref	30-19[191_179]|30-19[191_179]
28-44	4038-4046	analysis	abstract[179]	new[179]	_	_
28-45	4047-4049	is	_	_	_	_
28-46	4050-4060	unfeasible	_	_	_	_
28-47	4061-4062	.	_	_	_	_

#Text=Suspect and non-target screening are the two main strategies used for the exhaustive search of the known and unknown compound where almost no reference material is available .
29-1	4063-4070	Suspect	_	_	_	_
29-2	4071-4074	and	_	_	_	_
29-3	4075-4085	non-target	_	_	_	_
29-4	4086-4095	screening	abstract	new	coref	29-6[181_0]
29-5	4096-4099	are	_	_	_	_
29-6	4100-4103	the	abstract[181]	giv[181]	coref	30-9[0_181]
29-7	4104-4107	two	abstract[181]	giv[181]	_	_
29-8	4108-4112	main	abstract[181]	giv[181]	_	_
29-9	4113-4123	strategies	abstract[181]	giv[181]	_	_
29-10	4124-4128	used	_	_	_	_
29-11	4129-4132	for	_	_	_	_
29-12	4133-4136	the	event[182]	new[182]	_	_
29-13	4137-4147	exhaustive	event[182]	new[182]	_	_
29-14	4148-4154	search	event[182]	new[182]	_	_
29-15	4155-4157	of	event[182]	new[182]	_	_
29-16	4158-4161	the	event[182]|abstract[183]	new[182]|new[183]	coref	32-15[208_183]
29-17	4162-4167	known	event[182]|abstract[183]	new[182]|new[183]	_	_
29-18	4168-4171	and	event[182]|abstract[183]	new[182]|new[183]	_	_
29-19	4172-4179	unknown	event[182]|abstract[183]	new[182]|new[183]	_	_
29-20	4180-4188	compound	event[182]|abstract[183]	new[182]|new[183]	_	_
29-21	4189-4194	where	_	_	_	_
29-22	4195-4201	almost	_	_	_	_
29-23	4202-4204	no	abstract[185]	new[185]	_	_
29-24	4205-4214	reference	abstract|abstract[185]	new|new[185]	_	_
29-25	4215-4223	material	abstract[185]	new[185]	_	_
29-26	4224-4226	is	_	_	_	_
29-27	4227-4236	available	_	_	_	_
29-28	4237-4238	.	_	_	_	_

#Text=In recent years , the use of these screening techniques in the environmental field has greatly increased , particularly for the non-target analysis of pharmaceuticals , pesticides , hormones in surface and treated water .
30-1	4239-4241	In	_	_	_	_
30-2	4242-4248	recent	time[186]	new[186]	_	_
30-3	4249-4254	years	time[186]	new[186]	_	_
30-4	4255-4256	,	_	_	_	_
30-5	4257-4260	the	abstract[187]	new[187]	_	_
30-6	4261-4264	use	abstract[187]	new[187]	_	_
30-7	4265-4267	of	abstract[187]	new[187]	_	_
30-8	4268-4273	these	abstract[187]|abstract[189]	new[187]|new[189]	_	_
30-9	4274-4283	screening	abstract[187]|abstract|abstract[189]	new[187]|giv|new[189]	coref	34-3
30-10	4284-4294	techniques	abstract[187]|abstract[189]	new[187]|new[189]	_	_
30-11	4295-4297	in	abstract[187]|abstract[189]	new[187]|new[189]	_	_
30-12	4298-4301	the	abstract[187]|abstract[189]|abstract[190]	new[187]|new[189]|new[190]	_	_
30-13	4302-4315	environmental	abstract[187]|abstract[189]|abstract[190]	new[187]|new[189]|new[190]	_	_
30-14	4316-4321	field	abstract[187]|abstract[189]|abstract[190]	new[187]|new[189]|new[190]	_	_
30-15	4322-4325	has	_	_	_	_
30-16	4326-4333	greatly	_	_	_	_
30-17	4334-4343	increased	_	_	_	_
30-18	4344-4345	,	_	_	_	_
30-19	4346-4358	particularly	abstract[191]	giv[191]	coref	31-18[202_191]
30-20	4359-4362	for	abstract[191]	giv[191]	_	_
30-21	4363-4366	the	abstract[191]	giv[191]	_	_
30-22	4367-4377	non-target	abstract[191]	giv[191]	_	_
30-23	4378-4386	analysis	abstract[191]	giv[191]	_	_
30-24	4387-4389	of	abstract[191]	giv[191]	_	_
30-25	4390-4405	pharmaceuticals	abstract[191]|substance	giv[191]|new	_	_
30-26	4406-4407	,	abstract[191]	giv[191]	_	_
30-27	4408-4418	pesticides	abstract[191]|substance	giv[191]|new	_	_
30-28	4419-4420	,	abstract[191]	giv[191]	_	_
30-29	4421-4429	hormones	abstract[191]|substance[194]	giv[191]|new[194]	_	_
30-30	4430-4432	in	abstract[191]|substance[194]	giv[191]|new[194]	_	_
30-31	4433-4440	surface	abstract[191]|substance[194]|place	giv[191]|new[194]|new	_	_
30-32	4441-4444	and	abstract[191]	giv[191]	_	_
30-33	4445-4452	treated	abstract[191]|substance[196]	giv[191]|new[196]	coref	31-8[200_196]
30-34	4453-4458	water	abstract[191]|substance[196]	giv[191]|new[196]	_	_
30-35	4459-4460	.	_	_	_	_

#Text=Reversewise , the presence of cyanotoxins in surface water has only been investigated by few authors using this type of analysis .
31-1	4461-4472	Reversewise	abstract	new	_	_
31-2	4473-4474	,	_	_	_	_
31-3	4475-4478	the	abstract[198]	new[198]	_	_
31-4	4479-4487	presence	abstract[198]	new[198]	_	_
31-5	4488-4490	of	abstract[198]	new[198]	_	_
31-6	4491-4502	cyanotoxins	abstract[198]|object[199]	new[198]|giv[199]	coref	36-38[0_199]
31-7	4503-4505	in	abstract[198]|object[199]	new[198]|giv[199]	_	_
31-8	4506-4513	surface	abstract[198]|object[199]|substance[200]	new[198]|giv[199]|giv[200]	_	_
31-9	4514-4519	water	abstract[198]|object[199]|substance[200]	new[198]|giv[199]|giv[200]	_	_
31-10	4520-4523	has	_	_	_	_
31-11	4524-4528	only	_	_	_	_
31-12	4529-4533	been	_	_	_	_
31-13	4534-4546	investigated	_	_	_	_
31-14	4547-4549	by	_	_	_	_
31-15	4550-4553	few	person[201]	new[201]	_	_
31-16	4554-4561	authors	person[201]	new[201]	_	_
31-17	4562-4567	using	_	_	_	_
31-18	4568-4572	this	abstract[202]	giv[202]	coref	33-3[210_202]
31-19	4573-4577	type	abstract[202]	giv[202]	_	_
31-20	4578-4580	of	abstract[202]	giv[202]	_	_
31-21	4581-4589	analysis	abstract[202]	giv[202]	_	_
31-22	4590-4591	.	_	_	_	_

#Text=Isobaric interferences and co-eluting substances can represent major challenges in the identification process of a compound even when using HRMS .
32-1	4592-4600	Isobaric	abstract[203]	new[203]	_	_
32-2	4601-4614	interferences	abstract[203]	new[203]	_	_
32-3	4615-4618	and	_	_	_	_
32-4	4619-4629	co-eluting	substance[204]	new[204]	_	_
32-5	4630-4640	substances	substance[204]	new[204]	_	_
32-6	4641-4644	can	_	_	_	_
32-7	4645-4654	represent	_	_	_	_
32-8	4655-4660	major	abstract[205]	new[205]	_	_
32-9	4661-4671	challenges	abstract[205]	new[205]	_	_
32-10	4672-4674	in	abstract[205]	new[205]	_	_
32-11	4675-4678	the	abstract[205]|event[207]	new[205]|new[207]	_	_
32-12	4679-4693	identification	abstract[205]|abstract|event[207]	new[205]|giv|new[207]	coref	33-17[212_0]
32-13	4694-4701	process	abstract[205]|event[207]	new[205]|new[207]	_	_
32-14	4702-4704	of	abstract[205]|event[207]	new[205]|new[207]	_	_
32-15	4705-4706	a	abstract[205]|event[207]|abstract[208]	new[205]|new[207]|giv[208]	coref	33-32[216_208]
32-16	4707-4715	compound	abstract[205]|event[207]|abstract[208]	new[205]|new[207]|giv[208]	_	_
32-17	4716-4720	even	_	_	_	_
32-18	4721-4725	when	_	_	_	_
32-19	4726-4731	using	_	_	_	_
32-20	4732-4736	HRMS	abstract	giv	_	_
32-21	4737-4738	.	_	_	_	_

#Text=Moreover , a sole analysis , based on the accurate mass , is insufficient to confirm a structural identification , e. g. , determining the degradation by-products or metabolites related to a compound of interest .
33-1	4739-4747	Moreover	_	_	_	_
33-2	4748-4749	,	_	_	_	_
33-3	4750-4751	a	abstract[210]	giv[210]	_	_
33-4	4752-4756	sole	abstract[210]	giv[210]	_	_
33-5	4757-4765	analysis	abstract[210]	giv[210]	_	_
33-6	4766-4767	,	_	_	_	_
33-7	4768-4773	based	_	_	_	_
33-8	4774-4776	on	_	_	_	_
33-9	4777-4780	the	quantity[211]	giv[211]	coref	34-13[221_211]
33-10	4781-4789	accurate	quantity[211]	giv[211]	_	_
33-11	4790-4794	mass	quantity[211]	giv[211]	_	_
33-12	4795-4796	,	_	_	_	_
33-13	4797-4799	is	_	_	_	_
33-14	4800-4812	insufficient	_	_	_	_
33-15	4813-4815	to	_	_	_	_
33-16	4816-4823	confirm	_	_	_	_
33-17	4824-4825	a	abstract[212]	giv[212]	coref	34-38[0_212]
33-18	4826-4836	structural	abstract[212]	giv[212]	_	_
33-19	4837-4851	identification	abstract[212]	giv[212]	_	_
33-20	4852-4853	,	_	_	_	_
33-21	4854-4856	e.	_	_	_	_
33-22	4857-4859	g.	_	_	_	_
33-23	4860-4861	,	_	_	_	_
33-24	4862-4873	determining	_	_	_	_
33-25	4874-4877	the	substance[214]	new[214]	_	_
33-26	4878-4889	degradation	abstract|substance[214]	new|new[214]	_	_
33-27	4890-4901	by-products	substance[214]	new[214]	_	_
33-28	4902-4904	or	_	_	_	_
33-29	4905-4916	metabolites	substance	new	_	_
33-30	4917-4924	related	_	_	_	_
33-31	4925-4927	to	_	_	_	_
33-32	4928-4929	a	abstract[216]	giv[216]	_	_
33-33	4930-4938	compound	abstract[216]	giv[216]	_	_
33-34	4939-4941	of	abstract[216]	giv[216]	_	_
33-35	4942-4950	interest	abstract[216]	giv[216]	_	_
33-36	4951-4952	.	_	_	_	_

#Text=A non-target screening method should include various confirmatory elements , such as the accurate mass ( m/z ) , mass defect , isotopic pattern , charge states , adducts and fragmentation pattern that increase the confidence of identification .
34-1	4953-4954	A	abstract[218]	new[218]	_	_
34-2	4955-4965	non-target	abstract[218]	new[218]	_	_
34-3	4966-4975	screening	abstract|abstract[218]	giv|new[218]	coref	35-1[234_0]
34-4	4976-4982	method	abstract[218]	new[218]	_	_
34-5	4983-4989	should	_	_	_	_
34-6	4990-4997	include	_	_	_	_
34-7	4998-5005	various	abstract[220]	new[220]	_	_
34-8	5006-5018	confirmatory	place|abstract[220]	new|new[220]	_	_
34-9	5019-5027	elements	abstract[220]	new[220]	_	_
34-10	5028-5029	,	abstract[220]	new[220]	_	_
34-11	5030-5034	such	abstract[220]	new[220]	_	_
34-12	5035-5037	as	abstract[220]	new[220]	_	_
34-13	5038-5041	the	abstract[220]|quantity[221]	new[220]|giv[221]	appos	34-17[0_221]
34-14	5042-5050	accurate	abstract[220]|quantity[221]	new[220]|giv[221]	_	_
34-15	5051-5055	mass	abstract[220]|quantity[221]	new[220]|giv[221]	_	_
34-16	5056-5057	(	_	_	_	_
34-17	5058-5061	m/z	quantity	giv	coref	34-20
34-18	5062-5063	)	_	_	_	_
34-19	5064-5065	,	_	_	_	_
34-20	5066-5070	mass	quantity|abstract[224]	giv|new[224]	_	_
34-21	5071-5077	defect	abstract[224]	new[224]	_	_
34-22	5078-5079	,	_	_	_	_
34-23	5080-5088	isotopic	abstract|abstract[226]	new|new[226]	_	_
34-24	5089-5096	pattern	abstract[226]	new[226]	_	_
34-25	5097-5098	,	_	_	_	_
34-26	5099-5105	charge	abstract|abstract[228]	new|new[228]	_	_
34-27	5106-5112	states	abstract[228]	new[228]	_	_
34-28	5113-5114	,	_	_	_	_
34-29	5115-5122	adducts	abstract	new	_	_
34-30	5123-5126	and	_	_	_	_
34-31	5127-5140	fragmentation	abstract|abstract[231]	new|new[231]	_	_
34-32	5141-5148	pattern	abstract[231]	new[231]	_	_
34-33	5149-5153	that	_	_	_	_
34-34	5154-5162	increase	_	_	_	_
34-35	5163-5166	the	abstract[232]	new[232]	_	_
34-36	5167-5177	confidence	abstract[232]	new[232]	_	_
34-37	5178-5180	of	abstract[232]	new[232]	_	_
34-38	5181-5195	identification	abstract[232]|abstract	new[232]|giv	coref	36-13[240_0]
34-39	5196-5197	.	_	_	_	_

#Text=Suspect screening includes the benefit and disadvantage to depend on suspect lists .
35-1	5198-5205	Suspect	abstract[234]	giv[234]	_	_
35-2	5206-5215	screening	abstract[234]	giv[234]	_	_
35-3	5216-5224	includes	_	_	_	_
35-4	5225-5228	the	abstract[235]	new[235]	_	_
35-5	5229-5236	benefit	abstract[235]	new[235]	_	_
35-6	5237-5240	and	_	_	_	_
35-7	5241-5253	disadvantage	abstract	new	ana	36-1
35-8	5254-5256	to	_	_	_	_
35-9	5257-5263	depend	_	_	_	_
35-10	5264-5266	on	_	_	_	_
35-11	5267-5274	suspect	object[237]	new[237]	_	_
35-12	5275-5280	lists	object[237]	new[237]	_	_
35-13	5281-5282	.	_	_	_	_

#Text=It is mainly based on some of the information mentioned above for the identification , but a major drawback comes from a lack of data in online libraries for some small molecule families , i. e. , cyanotoxins , which allow a formal identification .
36-1	5283-5285	It	abstract	giv	_	_
36-2	5286-5288	is	_	_	_	_
36-3	5289-5295	mainly	_	_	_	_
36-4	5296-5301	based	_	_	_	_
36-5	5302-5304	on	_	_	_	_
36-6	5305-5309	some	_	_	_	_
36-7	5310-5312	of	_	_	_	_
36-8	5313-5316	the	abstract[239]	new[239]	_	_
36-9	5317-5328	information	abstract[239]	new[239]	_	_
36-10	5329-5338	mentioned	_	_	_	_
36-11	5339-5344	above	_	_	_	_
36-12	5345-5348	for	_	_	_	_
36-13	5349-5352	the	abstract[240]	giv[240]	coref	36-42[248_240]
36-14	5353-5367	identification	abstract[240]	giv[240]	_	_
36-15	5368-5369	,	_	_	_	_
36-16	5370-5373	but	_	_	_	_
36-17	5374-5375	a	abstract[241]	new[241]	_	_
36-18	5376-5381	major	abstract[241]	new[241]	_	_
36-19	5382-5390	drawback	abstract[241]	new[241]	_	_
36-20	5391-5396	comes	_	_	_	_
36-21	5397-5401	from	_	_	_	_
36-22	5402-5403	a	quantity[242]	new[242]	_	_
36-23	5404-5408	lack	quantity[242]	new[242]	_	_
36-24	5409-5411	of	quantity[242]	new[242]	_	_
36-25	5412-5416	data	quantity[242]|abstract	new[242]|new	_	_
36-26	5417-5419	in	quantity[242]	new[242]	_	_
36-27	5420-5426	online	quantity[242]|place[244]	new[242]|new[244]	_	_
36-28	5427-5436	libraries	quantity[242]|place[244]	new[242]|new[244]	_	_
36-29	5437-5440	for	quantity[242]|place[244]	new[242]|new[244]	_	_
36-30	5441-5445	some	quantity[242]|place[244]|abstract[246]	new[242]|new[244]|giv[246]	_	_
36-31	5446-5451	small	quantity[242]|place[244]|abstract[246]	new[242]|new[244]|giv[246]	_	_
36-32	5452-5460	molecule	quantity[242]|place[244]|abstract|abstract[246]	new[242]|new[244]|new|giv[246]	_	_
36-33	5461-5469	families	quantity[242]|place[244]|abstract[246]	new[242]|new[244]|giv[246]	_	_
36-34	5470-5471	,	_	_	_	_
36-35	5472-5474	i.	_	_	_	_
36-36	5475-5477	e.	_	_	_	_
36-37	5478-5479	,	_	_	_	_
36-38	5480-5491	cyanotoxins	object	giv	_	_
36-39	5492-5493	,	_	_	_	_
36-40	5494-5499	which	_	_	_	_
36-41	5500-5505	allow	_	_	_	_
36-42	5506-5507	a	abstract[248]	giv[248]	_	_
36-43	5508-5514	formal	abstract[248]	giv[248]	_	_
36-44	5515-5529	identification	abstract[248]	giv[248]	_	_
36-45	5530-5531	.	_	_	_	_

#Text=Nonetheless , considering the possibility to build specific in-house databases for the unambiguous identification of the known and unknown cyanopeptides is promising for the study and identification of less known congeners .
37-1	5532-5543	Nonetheless	_	_	_	_
37-2	5544-5545	,	_	_	_	_
37-3	5546-5557	considering	_	_	_	_
37-4	5558-5561	the	abstract[249]	new[249]	_	_
37-5	5562-5573	possibility	abstract[249]	new[249]	_	_
37-6	5574-5576	to	_	_	_	_
37-7	5577-5582	build	_	_	_	_
37-8	5583-5591	specific	abstract[250]	new[250]	_	_
37-9	5592-5600	in-house	abstract[250]	new[250]	_	_
37-10	5601-5610	databases	abstract[250]	new[250]	_	_
37-11	5611-5614	for	_	_	_	_
37-12	5615-5618	the	abstract[251]	new[251]	_	_
37-13	5619-5630	unambiguous	abstract[251]	new[251]	_	_
37-14	5631-5645	identification	abstract[251]	new[251]	_	_
37-15	5646-5648	of	abstract[251]	new[251]	_	_
37-16	5649-5652	the	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
37-17	5653-5658	known	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
37-18	5659-5662	and	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
37-19	5663-5670	unknown	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
37-20	5671-5684	cyanopeptides	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
37-21	5685-5687	is	_	_	_	_
37-22	5688-5697	promising	_	_	_	_
37-23	5698-5701	for	_	_	_	_
37-24	5702-5705	the	abstract[253]	new[253]	_	_
37-25	5706-5711	study	abstract[253]	new[253]	_	_
37-26	5712-5715	and	_	_	_	_
37-27	5716-5730	identification	abstract[254]	new[254]	_	_
37-28	5731-5733	of	abstract[254]	new[254]	_	_
37-29	5734-5738	less	abstract[254]|substance[255]	new[254]|giv[255]	_	_
37-30	5739-5744	known	abstract[254]|substance[255]	new[254]|giv[255]	_	_
37-31	5745-5754	congeners	abstract[254]|substance[255]	new[254]|giv[255]	_	_
37-32	5755-5756	.	_	_	_	_
